enow.com Web Search

  1. Ads

    related to: canada copd inhalers

Search results

  1. Results from the WOW.Com Content Network
  2. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

    en.wikipedia.org/wiki/Fluticasone_furoate/...

    Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [6] [7] The medications work in different ways: fluticasone furoate is an inhaled corticosteroid ...

  3. Olodaterol - Wikipedia

    en.wikipedia.org/wiki/Olodaterol

    Olodaterol is a once-daily maintenance bronchodilator treatment of airflow obstruction in people with COPD. [3] While it appears to reduce COPD exacerbations it does not appear to alter the speed at which a person's lungs worsen or alter their life expectancy. [3] As of December 2013, olodaterol is not approved as a treatment of asthma.

  4. Ensifentrine - Wikipedia

    en.wikipedia.org/wiki/Ensifentrine

    [7]: 19–20 Rhinopharma was a startup founded in Vancouver, Canada in 2004 by Michael Walker, Clive Page, and David Saint, to discover and develop drugs for chronic respiratory diseases, [7]: 16 and intended to develop ensifentrine, delivered with an inhaler, first for allergic rhinitis, then asthma, then for COPD.

  5. GSK to cap out-of-pocket inhaler costs in US - AOL

    www.aol.com/news/gsk-cap-pocket-inhaler-costs...

    The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

  6. Vilanterol - Wikipedia

    en.wikipedia.org/wiki/Vilanterol

    Vilanterol is an ultra-long-acting β 2-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). [1] [2] The combination is also approved for the treatment of asthma in Canada, Europe, Japan [3] and ...

  7. AstraZeneca to cap US out-of-pocket costs for inhalers at $35 ...

    www.aol.com/news/astrazeneca-cap-us-pocket-costs...

    The cap would apply to all its respiratory products portfolio, including inhalers to treat asthma and chronic obstructive pulmonary disease (COPD), AstraZeneca said. Boehringer had also said it ...

  1. Ads

    related to: canada copd inhalers